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Background: Although beta-blockers (BB) reduce mortality in patients (Pts) with heart failure (HF), genetic differences in neurohormonal 
activation may limit effectiveness. Systematic review identified 3 adrenergic receptor SNPs as primary candidates. We report on the beta-1 receptor 
Gly49 variant that results in agonist-induced receptor down-regulation in vitro. We hypothesized Gly49-carriers would have reduced response to BB 
compared to Ser49-homozygotes.
Methods: This hypothesis was tested in the UNITE-HF DNA Registry, a prospective, observational, multicenter study of the genomics of HF in US Pts 
seen in HF specialty clinics. Data on BB use and survival (death index) were examined in Pts mostly enrolled from 2000-2002. Adjusted Cox models 
(including race) assessed BB*Ser49Gly interaction and the association between BB and survival stratified by Ser49Gly genotype.
Results: Data were available in 715 Pts on baseline BB use, vital status and Ser49Gly genotype (68% Ser49-homozygous and 32% Gly49-
carriers). The cohort was 63% male, 38% African-American (AA) and 44% ischemic etiology. Age of the cohort was 57±13 years (mean±SD), LVEF 
32±16%, NYHA class 2.5±0.6 and SBP 119±22 mmHg. Baseline drug use included ACEI or ARB (89%), diuretics (89%) and spironolactone (24%). 
BB utilization was 68% consistent with the enrollment period. Baseline characteristics were similar by genotype except AA race (33% Ser49-
homozygotes vs 49% Gly49-carriers, p<0.001). There were 348 deaths (52% Gly49-carriers, 47% Ser49-homozygotes) at an average follow-up of 
6.9±3.6 years. BB use was associated with reduced mortality in the overall study population (adjusted HR=0.72, 95% CI 0.56 - 0.91, p=0.004) and 
Ser49-homozygotes (adjusted HR=0.56, 95% CI 0.42 - 0.75, p<0.001) but not Gly49-carriers (adjusted HR=1.28, 95% CI 0.80 - 2.04, p=0.31). The 
adjusted interaction between Ser49Gly genotype and BB association with overall survival was p=0.004. These findings were independent of race (AA 
vs Non-AA).
Conclusions: In this US sample, BB use was associated with prolonged survival in Ser49 homozygotes, but not in Gly49-carriers. This novel 
hypothesis-generating finding warrants replication in a prospective trial.
